New drug candidate ENA-001 takes first step in human trials
NCT ID NCT06967259
First seen Jan 05, 2026 · Last updated Apr 28, 2026 · Updated 19 times
Summary
This early-stage study tests the safety of a new drug called ENA-001 in 36 healthy volunteers. The drug is given as a single shot into a vein or muscle to see how the body handles it and if it causes any side effects. This research is a first step toward a possible treatment for respiratory depression, a condition where breathing becomes dangerously slow or shallow.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RESPIRATORY DEPRESSION are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Clinilabs
Eatontown, New Jersey, 07724, United States
-
Dr. Vince Clinical Research
Overland Park, Kansas, 66212, United States
Conditions
Explore the condition pages connected to this study.